China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with South Korea’s ABL Bio Inc. (KOSDAQ: 298380) to advance the development of bispecific antibody drug conjugates (ADCs).
ABL Bio is a research-driven biotechnology firm recognized for its pioneering work in bispecific antibodies aimed at treating immuno-oncology and neurodegenerative diseases. Biocytogen, on the other hand, leverages its RenLite mouse platform, a cutting-edge technology capable of generating fully human antibodies with high affinity that identify multiple epitopes. This innovative platform allows for the production of common light chain antibodies, providing exceptional design flexibility in dual antibody ADCs, while simplifying the production process and enhancing overall drug performance. Future collaborations between the two companies may extend to various ADC development avenues, broadening the scope of their combined expertise.- Flcube.com
